Inverse, protean, and ligand‐selective agonism: matters of receptor conformation
Top Cited Papers
- 19 January 2001
- journal article
- review article
- Published by Wiley in The FASEB Journal
- Vol. 15 (3) , 598-611
- https://doi.org/10.1096/fj.00-0438rev
Abstract
Concepts regarding the mechanisms by which drugs activate receptors to produce physiological response have progressed beyond considering the receptor as a simple on-off switch. Current evidence suggests that the idea that agonists produce only varying degrees of receptor activation is obsolete and must be reconciled with data to show that agonist efficacy has texture as well as magnitude. Thus, agonists can block system constitutive response (inverse agonists), behave as positive and inverse agonists on the same receptor (protean agonists), and differ in the stimulus pattern they produce in physiological systems (ligand-selective agonists). The molecular mechanism for this seemingly diverse array of activities is the same, namely, the selective microaffinity of ligands for different conformational states of the receptor. This paper reviews evidence for the existence of the various types of agonism and the potential therapeutic utility of different agonist types.—Kenakin, T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation.Keywords
This publication has 93 references indexed in Scilit:
- The Cubic Ternary Complex Receptor-Occupancy Model III. Resurrecting EfficacyJournal of Theoretical Biology, 1996
- The Cubic Ternary Complex Receptor–Occupancy Model II. Understanding Apparent AffinityJournal of Theoretical Biology, 1996
- The Cubic Ternary Complex Receptor–Occupancy Model I. Model DescriptionJournal of Theoretical Biology, 1996
- Agonist-receptor efficacy I: mechanisms of efficacy and receptor promiscuityTrends in Pharmacological Sciences, 1995
- Expanding horizons for receptors coupled to G proteins: diversity and diseaseCurrent Opinion in Cell Biology, 1994
- Amino acids 356–372 constitute a Gi‐activator sequence of the α2‐adrenergic receptor and have a Phe substitute in the G protein‐activator sequence motifFEBS Letters, 1992
- A heterozygous 4-bp deletion mutation in the Gsα gene (GNAS1) in a patient with albright hereditary osteodystrophyGenomics, 1992
- Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.Gut, 1991
- Two G Protein Oncogenes in Human Endocrine TumorsScience, 1990
- The mitogenic effects of vasoactive neuropeptides on cultured smooth muscle cell linesLife Sciences, 1987